Please login to the form below

Not currently logged in
Email:
Password:

Shire lines up Advanced BioHealing deal

Shire is to acquire Advanced BioHealing, a US-based regenerative medicine company, for $750m in cash

Shire has acquired Advanced BioHealing, a US-based regenerative medicine company, for $750m in cash. The deal will see Shire own the global rights for DERMAGRAFT, a regenerative bio-engineered skin substitute indicated for use in the treatment of diabetic foot ulcers greater than six weeks in duration, and will continue to invest in the development of new indications and new geographies, pending regulatory approvals.  

Mike Cola, president of Shire's Specialty Pharmaceuticals business, said: "This acquisition is a strong and complementary strategic fit for Shire. We will invest in the strengths of Advanced BioHealing's specialist commercial team, its manufacturing and its product development.

“We believe there's an opportunity to create more value from DERMAGRAFT and Advanced BioHealing's proprietary technology and that with Advanced BioHealing's team joining Shire, we can build Advanced BioHealing into an exciting new business providing regenerative medicine for patients' unmet needs."

The deal is subject to customary conditions, including obtaining anti-trust clearances.

18th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....
Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...

Infographics